Workshops

ATHEROSCLEROSIS – PATHOPHYSIOLOGY AND MECHANISMS

1.1 Progression and regression of atherosclerosis

Regression of atherosclerosis: from mechanisms to treatment

Edward Fisher, New York, USA

Advances in measuring plaque regression

Stephen Nicholls, Adelaide, Australia

1.2 Cellular biology of the vessel wall

The importance of cholesterol in driving SMC trans differentiation in diseased plaque

Gordon A. Francis, Vancouver, Canada

MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis

Christian Weber, Munich, Germany

1.3 Role of macrophages in atherogenesis

Genome-wide approaches to understanding roles of macrophages in atherosclerosis and metabolic

Christopher Glass, San Diego, USA

Cholesterol crystals and inflammation

Eicke Latz, Bonn, Germany

1.4 Immunometabolism: the interface of immune and metabolic responses in disease

Cholesterol biosynthetic flux and immunity

Steven J. Bensinger, Los Angeles, USA

Metabolic pathways in immune cells

Federica Marelli-Berg, London, United Kingdom

LIPIDS, LIPOPROTEINS AND LIPID METABOLISM

2.1 Extracellular lipid metabolism (apolipoproteins and lipid metabolism)

Sortilins: new players in cardiovascular and other metabolic diseases

Anders Nykjaer, Aarhus, Denmark

The role of ANGPTL3 in controlling lipoprotein metabolism

Sander Kersten, Wageningen, Netherlands

2.2 Cellular lipid metabolism

Fatty acid metabolism in the human heart

André C. Carpentier, Quebec, Canada

Lipases and lipolysis in cellular lipid metabolism and signaling

Dagmar Kratky, Graz, Austria

2.3 Moderating LDL levels by regulating LDL receptors

Focus on SREBPs

Jay D. Horton, Dallas, USA

Deubiquitylase USP2 and LDL-R biology

Noam Zelcer, Amsterdam, Netherlands

2.4 Regulators of metabolism and cardiometabolic disease

Circadian control of metabolism

Frank A. J. L. Scheer, Boston, USA

Brown adipose tissue: a novel target to comBAT cardiometabolic disease

Patrick Rensen, Leiden, Netherlands

EPIDEMIOLOGY, DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

3.1 Genetics and epidemiology of cardiovascular diseases and dyslipidaemia

Using naturally randomized genetic evidence to understand heritability of coronary artery disease?

Brian A. Ference, Detroit, USA

Prognostics in patients with manifest (acute or chronic) CHD

Thomas F. Lüscher, Zurich, Switzerland

3.2 Novel treatments of dyslipideamia

Hypertriglyceridaemia: ApoC-III and ANGPTL3

Sotirios Tsimikas, San Diego, USA

HDL-cholesterol and cardiovascular disease: rethinking our approach

John M. Chapman, Paris, France